The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Upholding a role for EMT in breast cancer metastasis
Open accessAbstract
The cell-biological program termed the epithelial-to-mesenchymal transition (EMT) has been invoked as a critical component of the meta static process. Contrastingly, Fischer et al.1 recently reported that in two genetically engineered mouse models of mammary tumour deve lopment, carcinoma cells could metastasize without activating EMT programs. However, as detailed below, we find their evidence that EMT programs were not expressed in these primary tumours to be insufficient. Therefore, the contribution of EMT to carcinoma meta stasis could not be ruled out in their analysis. There is a Reply to this Comment by Fischer, K. R. et al. Nature 547, http://dx.doi.org/10.1038/nature22817 (2017). It has been well-established that the EMT is not a single, stereotypical program2–4. Instead, it represents a group of related cellbiological programs, each of which confers certain mesenchymal traits on epithelial cells. Its variability stems from the facts that (1) it can be induced by expression of multiple alternative transcription factors5–9; (2) cells activating an EMT program often proceed only part-way towards a fully mesenchymal state, acquiring only a fraction of various mesenchymal markers2,10,11 and such partial and reversible activation of EMT has been shown to be critical for metastasis12–15; and (3) EMT programs may be manifested in different ways in different tissues2–4,12. These considerations help to illuminate the EMT programs analysed in the publications by Fischer et al.1, who concluded that metastasis from primary tumours occurred in the absence of EMT activation. Fischer et al.1 employed the Cre/CreER lineage-tracing method to track carcinoma cells that have undergone EMT activation. In such a genetic tracing protocol, the promoter of interest drives the expression of the Cre recombinase, which in turn inflicts a stable genetic mark on the genome of a cell and its lineal descendants. A derivation of this basic protocol involves a CreER protein, which only functions when a ligand of the oestrogen receptor (ER), in this case tamoxifen, is present. Hence, the marking of a cell depends on the concomitant presence of CreER expression and experimentally supplemented tamoxifen. In the present case, the authors used a Cre-activatable GFP transgene; accordingly, transient actions of Cre/CreER would permanently turn off an RFP marker and activate a GFP reporter. By monitoring the expression of GFP, Fischer et al.1 would therefore be able to determine whether an ancestor of these cells had expressed Cre/CreER. In order for the lineage tracing system to effectively mark carcinoma cells that have undergone EMT activation, it needs to meet, in our view, at least two criteria (Fig. 1a). First, the Cre/CreER driver needs to be expressed in most if not all of the cells that transiently undergo EMT activation. Second, once expressed, the Cre/CreER protein needs to activate the GFP reporter in most if not all of the carcinoma cells where Cre/CreER is expressed. Fischer et al.1 chose to use transgenic Cre/CreER lines driven by the promoters of two genes, Fsp1 and Vim, that are known to be expressed in certain versions of the EMT program. For most of their analyses, they used an Fsp1-cre transgene. The authors portrayed Fsp1 as a “critical gatekeeping gene” of EMT initiation, based on a publication showing that Fsp1 is required in order for renal proximal tubular epithelial cells to undergo an EMT in vitro in response to TGFβ16. If this portrayal of the gatekeeper role of Fsp1 were accurate, this would qualify its expression as a sensitive indicator of EMT activation. However, given the variable manifestations of the EMT program in various tissues2–4,14, there is no reason to believe that a marker of EMT activation in renal tubular cells will serve as a useful indicator in unrelated tissues, in this case the mammary epithelium. In fact, there is abundant evidence that Fsp1 is not an integral component of all EMT programs17, as Fsp1-knockout mice are capable of undergoing all stages of developmental EMT and are viable and fertile18. Moreover, in our own studies, while we could indeed
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Self-citationTwist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., & Weinberg, R. A. (2004) · Cell · doi:10.1016/j.cell.2004.06.006 · Cited by 3,855
Self-citationCano, A., Pérez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., Portillo, F., & Nieto, M. A. (2000) · Nature Cell Biology · doi:10.1038/35000025 · Cited by 3,668
Self-citationBatlle, E., Sancho, E., Francí, C., Domínguez, D., Monfar, M., Baulida, J., & García de Herreros, A. (2000) · Nature Cell Biology · doi:10.1038/35000034 · Cited by 2,666
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., Isakoff, S. J., Ciciliano, J. C., Wells, M. N., Shah, A. M., et al. (2013) · Science · doi:10.1126/science.1228522 · Cited by 2,476
Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015) · Nature · doi:10.1038/nature15748 · Cited by 1,791
The Two-Handed E Box Binding Zinc Finger Protein SIP1 Downregulates E-Cadherin and Induces Invasion
Comijn, J., Berx, G., Vermassen, P., Verschueren, K., van Grunsven, L., Bruyneel, E., Mareel, M., Huylebroeck, D., & van Roy, F. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00260-x · Cited by 1,394
Bolós, V., Peinado, H., Pérez-Moreno, M. A., Fraga, M. F., Esteller, M., & Cano, A. (2003) · Journal of Cell Science · doi:10.1242/jcs.00224 · Cited by 1,100
Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S., & Yang, J. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.022 · Cited by 1,071
Self-citationOcaña, O. H., Córcoles, R., Fabra, Á., Moreno-Bueno, G., Acloque, H., Vega, S., Barrallo-Gimeno, A., Cano, A., & Nieto, M. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.012 · Cited by 973
Self-citation
Cited by
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
Dongre, A., & Weinberg, R. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0080-4 · Cited by 3,876
Self-citationEMT Transition States during Tumor Progression and Metastasis
Pastushenko, I., & Blanpain, C. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.12.001 · Cited by 2,876
Guidelines and definitions for research on epithelial-mesenchymal transition
Yang, J., Antin, P., Berx, G., Blanpain, C., Brabletz, T., Bronner, M., Campbell, K., Cano, A., Casanova, J., Christofori, G., et al. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0237-9 · Cited by 2,226
Self-citationBrabletz, T., Kalluri, R., Nieto, M. A., & Weinberg, R. A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.118 · Cited by 1,961
Self-citationIdentification of the tumour transition states occurring during EMT
Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., Van Keymeulen, A., Brown, D., Moers, V., Lemaire, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0040-3 · Cited by 1,495
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.001 · Cited by 1,486
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis
Huang, Y., Hong, W., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01347-8 · Cited by 1,032
Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis
Lu, W., & Kang, Y. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.010 · Cited by 1,030
Self-citationEMT, MET, Plasticity, and Tumor Metastasis
Bakir, B., Chiarella, A. M., Pitarresi, J. R., & Rustgi, A. K. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.07.003 · Cited by 1,010
Tong, X., Tang, R., Xiao, M., Xu, J., Wang, W., Zhang, B., Liu, J., Yu, X., & Shi, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01392-3 · Cited by 883
Context-dependent EMT programs in cancer metastasis
Aiello, N. M., & Kang, Y. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181827 · Cited by 584
Self-citationLinking EMT programmes to normal and neoplastic epithelial stem cells
Lambert, A. W., & Weinberg, R. A. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00332-6 · Cited by 534
Self-citationA history of exploring cancer in context
Maman, S., & Witz, I. P. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0006-7 · Cited by 502
Non-redundant functions of EMT transcription factors
Stemmler, M. P., Eccles, R. L., Brabletz, S., & Brabletz, T. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0196-y · Cited by 524
Self-citationControversies around epithelial–mesenchymal plasticity in cancer metastasis
Williams, E. D., Gao, D., Redfern, A., & Thompson, E. W. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0213-x · Cited by 451
A conduit to metastasis: circulating tumor cell biology
Micalizzi, D. S., Maheswaran, S., & Haber, D. A. (2017) · Genes & Development · doi:10.1101/gad.305805.117 · Cited by 446
Lüönd, F., Tiede, S., & Christofori, G. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01328-7 · Cited by 427
Distinct contributions of partial and full EMT to breast cancer malignancy
Lüönd, F., Sugiyama, N., Bill, R., Bornes, L., Hager, C., Tang, F., Santacroce, N., Beisel, C., Ivanek, R., Bürglin, T., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.11.006 · Cited by 391
Pleiotropic Roles for ZEB1 in Cancer
Caramel, J., Ligier, M., & Puisieux, A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2476 · Cited by 344
Factors involved in cancer metastasis: a better understanding to “seed and soil” hypothesis
Liu, Q., Zhang, H., Jiang, X., Qian, C., Liu, Z., & Luo, D. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0742-4 · Cited by 332
microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1
Wang, H., Tan, Z., Hu, H., Liu, H., Wu, T., Zheng, C., Wang, X., Luo, Z., Wang, J., Liu, S., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5951-3 · Cited by 304
Epithelial plasticity, epithelial-mesenchymal transition, and the TGF-β family
Katsuno, Y., & Derynck, R. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.02.028 · Cited by 187
Epithelial-Mesenchymal Transition and Metastasis under the Control of Transforming Growth Factor β
Tsubakihara, Y., & Moustakas, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113672 · Cited by 160
van Staalduinen, J., Baker, D., ten Dijke, P., & van Dam, H. (2018) · Oncogene · doi:10.1038/s41388-018-0378-x · Cited by 158
Emerging roles and therapeutic value of exosomes in cancer metastasis
Wu, M., Wang, G., Hu, W., Yao, Y., & Yu, X.-F. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0964-8 · Cited by 140
The Cell Biology of Metastatic Invasion in Pancreatic Cancer: Updates and Mechanistic Insights
Joshi, V. B., Gutierrez Ruiz, O. L., & Razidlo, G. L. (2023) · Cancers · doi:10.3390/cancers15072169 · Cited by 32
Metadata
- Authors
- Ye, X., Brabletz, T., Kang, Y., Longmore, G. D., Nieto, M. A., Stanger, B. Z., Yang, J., & Weinberg, R. A.
- Venue
- Nature
- Published
- 2017-07-06
- Volume
- 547
- Issue
- 7661
- Pages
- E1-E3
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2733398634
- Cited by
- 333
- References
- 21
- FWCI
- 17.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.